Schering AG has announced the start of three Phase II studies in Europe evaluating its fully synthetic epothilone, ZK-EPO, for the treatment of several types of cancers such as non-small cell lung cancer, ovarian cancer and breast cancer. The clinical trials will assess ZK-EPO's safety and efficacy in each of these cancer types. ZK-EPO is the only fully synthetic epothilone in clinical development. It is designed to improve efficacy and safety compared to currently available chemotherapies.
In non-small cell lung cancer, a multicenter study is currently enrolling patients in Germany. The trial is designed to examine the efficacy and safety of ZK-EPO as second-line therapy in patients with advanced disease.
The ovarian cancer trial is a multicenter Phase II study that is being conducted in the UK. The study is currently enrolling patients with recurrent ovarian cancer.
The breast cancer trial will enroll patients in 24 medical centers in a number of European countries. The first study centers have been initiated in France and Austria. The trial will investigate the efficacy of ZK-EPO in patients with metastatic breast cancer.